Explore

Trendline Trendline
Spruce Biosciences Prices Public Offering to Raise $60 Million

Spruce Biosciences Prices Public Offering to Raise $60 Million

Spruce Biosciences Prices Public Offering to Raise $60 Million
Trendline Trendline
Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Initiates Public Offering of Common Stock and Pre-Funded Warrants
Trendline Trendline
Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants
Trendline Trendline
Southern First Bancshares Reports Strong First Quarter 2026 Financial Results

Southern First Bancshares Reports Strong First Quarter 2026 Financial Results

Southern First Bancshares Reports Strong First Quarter 2026 Financial Results
Trendline Trendline
Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42

Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42

Eluciderm, Inc. Awarded for Innovative Wound Healing Research with ELU42
Trendline Trendline
Arrowhead Pharmaceuticals to Announce Fiscal 2026 Q2 Results via Webcast

Arrowhead Pharmaceuticals to Announce Fiscal 2026 Q2 Results via Webcast

Arrowhead Pharmaceuticals to Announce Fiscal 2026 Q2 Results via Webcast
Trendline Trendline
Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value

Revolution Medicine's Pancreatic Cancer Trial Results Boost Stock Value
Trendline Trendline
Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence
Trendline Trendline
ImmunityBio Faces Securities Fraud Lawsuit with May 2026 Deadline for Leadership

ImmunityBio Faces Securities Fraud Lawsuit with May 2026 Deadline for Leadership

ImmunityBio Faces Securities Fraud Lawsuit with May 2026 Deadline for Leadership
Trendline Trendline
Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action

Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action

Rosen Law Firm Advises Aldeyra Therapeutics Investors on May 29 Deadline in Securities Class Action
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation